(redirected from Biopure Corporation)
BPURBiopure Corporation (stock symbol)
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
The manager of the American Biopure Corporation in South Africa, Dr Mandisa Mholwana, is aware of our stand on this matter, which was communicated to her in writing in early 2008, and she agreed to delete any statement in their publications and website to the effect that Hemopure is acceptable to Jehovah's Witnesses.
In the canine model this product is already available in the form of Oxyglobin[R] (Biopure Corporation, Cambridge, MA) and is actually used by veterinarians during canine trauma surgery today.
Biopure Corporation (Cambridge, MA) has successfully defended a challenge at the European Patent Office to its European Patent entitled, "A Method for Chromatographic Removal of Prions." This European Patent covers Biopure's innovative purification method for removing potentially infectious prion proteins from oxygen therapeutics and provides Biopure with granted patent rights to its method in France, Germany, the United Kingdom, Ireland, Italy, Spain, and Switzerland.
Biopure Corporation (NASDAQ:BPUR), Cambridge, Mass., has been notified by the Food and Drug Administration (FDA) that the FDA's Blood Products Advisory Committee will meet on July 14, 2006 to discuss the Navy's proposed RESUS clinical trial of the company's investigational oxygen therapeutic Hemopure(R) [hemoglobin glutamer - 250 (bovine)] for out-of- hospital treatment of hemorrhagic shock resulting from traumatic injury.
Glutaraldehyde has been used to polymerize bovine hemoglobin (Oxyglobin[R] and Hemopure; Biopure Corporation) as well as pyridoxalated human hemoglobin (PolyHeme[R]; Northfield Laboratories), although a different cross-linking agent, O-raffinose, has also been used to polymerize human hemoglobin (HemolinkTM; Hemosol Ltd).
Biopure Corporation (NASDAQ:BPUR), Cambridge, Mass, has announced its financial results for the third fiscal quarter ended July 31, 2003.
Biopure Corporation of Cambridge, Mass., is a frontrunner in the race with a product based on hemoglobin extracted from the red blood cells of cows.
Food and Drug Administration (FDA) gave Biopure Corporation in Cambridge, Massachusetts, the green light to sell Oxyglobin to all veterinarians in the U.S.
After the establishment of appropriate Material Transfer and Confidentiality Agreements, the following HBOC products were provided by the respective pharmaceutical companies responsible for developing each product: Oxyglobin and Hemopure (glutaraldehyde-polymerized bovine Hb; Biopure Corporation), PolyHeme (glutaraldehydecross-linked pyridoxalated human Hb; Northfield Laboratories), PHP (pyridoxalated human Hb polyoxyethylene conjugate; Apex Bioscience Inc.), Hemospan (maleimide-polyethylene-glycol-conjugated human Hb; Sangart Inc.), and HemAssist (diaspirin-cross-linked human Hb; Baxter Healthcare Co.).
(KAG624) CARL RAUSCH, CEO of BIOPURE CORPORATION (BPUR), describes the company's business and its background; prospects for the industry, with positive and negative trends; competitive threats; strategic opportunities for the firm including its marketing plans and acquisition potential; management strength and organization; and the financial prospects of the firm looking forward.
Biopure Corporation (Cambridge, MA; 617-234-6826) announced that its investigational oxygen therapeutic, Hemopure (hemoglobin glutamer -- 250 (bovine)) has been shown to sustain myocardial tissue oxygenation and heart function during severe constriction of a coronary artery, according to results from a pharmacology study presented at the American Society of Anesthesiologists Annual Meeting this week in Dallas, Texas.